THE EFFICACY OF 3% TOPICAL TRANXEXAMIC ACID CREAM IN POST-ACNE ERYTHEMA POST-ACNE ERYTHEMA, TRANXEXAMIC ACID
Conditions
Interventions
Patients will be instructed to apply 3% topical tranexamic acid cream twice daily on their assigned sides of faces and apply placebo cream on the other sides of their faces as a control for 12 weeks.
Active Comparator Drug,Placebo Comparator Drug
3% tranexamic acid cream,cream base
Sponsors
Reseach and International Relations Division, Srinakharinwirot University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria 1. Female or Male patients aged over 18 years old. 2. Patients who have been diagnosed with persistent post acne erythema (PAE) with no or mild acne. 3. Patients who participate in the project voluntarily and sign the consent form. 4. Patients who are able to follow-up examination in the 4th, 8th, and 12th week.
Exclusion criteria
Exclusion criteria: 1. Patients who have moderate or severe acne vulgaris. 2. Patients who are concurrently treated with any other treatment for PEA for at least 3 months. 3. Patients with other facial conditions within the area treated that would interfere with PAE assessment or would be affected with the components of the topical treatment, which are tattoo, telangiectasia, melasma, rosacea, skin infection, dermatitis. 4. Female patients who are pregnant, lactating or planning to become pregnant during the study period. 5. Patients who had previous face procedures including chemical, energy-based device, laser or mechanical skin resurfacing, for at least 3 months prior to this study. 6. Patients who have history of treatment with systemic tranexamic acid within 1 months before and during this study. 7. Patients who have history of intracranial bleeding, defective color vision, arterial or venous thromboembolism or active thromboembolic disease. 8. Patients who have history of allergy to tranexamic acid 9. patients who are prescribed oral NSAIDS or oral retinoids. 10. Patients who have history of allergy to placebo ingredients: glycerin, butylene glycol, betaine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post Acne Erythema lesion count at week 0, 4, 8, 12 counting,. The Clinical Erythema Assessment scale at week 0, 4, 8, 12 acessor,erythema index at week 0, 4, 8,12 maxameter | — |
Secondary
| Measure | Time frame |
|---|---|
| Global Aesthetic Improvement scale (GAIS) at week 12 Global Aesthetic Improvement scale (GAIS) by patient,Post inflammation Hyperpigmentation lesion count at week 0, 4, 8, 12 counting,melanin index at week 0, 4, 8, 12 mexameter | — |
Countries
Thailand
Contacts
Public ContactPaveetida Tangam
Faculty of Medicine, Srinakharinwirot University
Outcome results
None listed